UBS, JMP Downgrades ACHN On JNJ Deal
TipRanks | May 21, 2015 08:47AM ET
Biotechnology company Achillion Pharmaceuticals (NASDAQ:ACHN) fell about 10% in trading on Wednesday, May 20 following the company’s announcement that it licensed its hepatitis C drug pipeline to Johnson & Johnson (NYSE:JNJ) for $1.1 billion.
In the terms of the deal, Johnson & Johnson will pay Achillion Pharmaceuticals milestone payments totaling $1.1 billion throughout the development of its hepatitis C drug. Johnson & Johnson will also purchase 18.4 million new shares in Achillion Pharmaceuticals for $12.25 a share, totaling $224 million.
Additionally, Johnson & Johnson will have exclusive rights to develop and commercialize the hepatitis C pipeline and will have to pay Achillion royalties on any future sales worldwide. The royalty percentages will range from the mid-teens to low-twenties.
Investors did not react too kindly to this news as they were expecting a distributor to buy Achillion’s hepatitis C drug pipeline outright.
Achillion CEO Milind Deshpande, Ph.D., said of the deal, “We believe that [Johnson & Johnson’s pharmaceutical R&D department] renowned expertise in HCV development and commercialization enables a synergistic opportunity to rapidly advance our combined HCV assets toward the market while simultaneously achieving an optimized treatment regimen for all HCV patients…Furthermore, we believe that their investment in Achillion through Johnson & Johnson Innovation – JJDC allows us to maximize the value from our HCV portfolio and also positions us to become a leader in complement factor D inhibition, applying our broad platform to a wide number of complement-related diseases. We believe this strategy provides an ideal scenario to create further value for our shareholders.”
UBS analyst Andrew Peters weighed in on Achillion Pharmaceuticals on May 20, downgrading his rating from Buy to Neutral and cutting his price target from $19 to $11.50. The analyst attributed his downgrade to the limited potential upside the Achillion and Johnson & Johnson collaboration has for the stock.
Overall, Andrew Peters has a 58% success rate recommending stocks and a +20.7% average return per recommendation.
Similarly on May 20, JMP Securities analyst Liisa Bayko downgraded her rating on Achillion Pharmaceuticals from Outperform to Market Perform with a price target of $24. The analyst believes the deal’s platform “appears to have blockbuster potential” but prefers to hold out until the company starts to benefit from outsourcing its hepatitis C virus pipeline.
Get The News You Want
Liisa Bayko has an overall success rate of 73% recommending stocks and a +55.2% average return per recommendation.
On average, the top analyst consensus for Achillion Pharmaceuticals on TipRanks is Hold.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.